LuxCath LLC, Awarded U.S. Patent for Real-time Lesion Visualization Technology Focused on Atrial Fibrillation Ablation
July 29 2015 - 2:00AM
Business Wire
- Groundbreaking innovation has immediate
market application in the catheter treatment of Atrial Fibrillation
(AF), the most common irregular heartbeat affliction.
- Technology directly interrogates
cardiac tissue using light in catheter-based embodiments to
optically identify naturally occurring fluorescing molecules.
- System determines electrode-tissue
contact as well as monitors lesion progression during ablation and
provides real-time lesion visualization without pressure sensors or
ultrasound.
LuxCath LLC, a medical technology company that is developing
catheter-based real-time tissue contact assessment, lesion
visualization, and lesion gap detection technology, announced today
that the U.S. Patent and Trademark Office (USPTO) has issued U.S.
Patent No. 9,084,611 entitled "Systems and Methods for Visualizing
Ablated Tissue.”
LuxCath’s technology for directly visualizing tissue and lesions
in real time has initial application in the treatment of Atrial
Fibrillation (AF). AF is the most common cardiac arrhythmia, or
irregular heartbeat, in the U.S., affecting more than 2 million
people, or about 1 in every 150 individuals. The relatively new but
minimally invasive procedure used to restore the heartbeat to a
normal pace, known as Radio Frequency Catheter Ablation (RFCA),
optimally requires a real-time, lesion-identifying, direct
visualization tool in order to be performed consistently,
effectively, quickly and safely.
“The benefits of directly interrogating the tissue optically in
real time allow us to understand if we have good contact with the
tissue while also revealing enormous amounts of information about
the tissue before, during and after the ablation, which previously
had not been available,” said Dr. Omar Amirana, M.D., LuxCath Chief
Executive Officer and Senior Vice President at Boston-based Allied
Minds. “We are introducing new windows into the science of ablation
therapy for all arrhythmias with this technology. While we are
focused on AF, this should significantly improve clinical outcomes,
reduce procedure times, minimize procedure costs, and positively
impact burdensome re-treatments for all ablation procedures.”
LuxCath’s technology can monitor tissue ablation in real time to
help ensure the elimination of gaps of viable tissue between the
lesions during an RFCA procedure. The technology also has the
benefit of determining the quality of electrode-tissue contact.
This medical innovation is based on collaborative research and
development with researchers and faculty at the George Washington
University, as well as the product development team at Nocturnal
Product Development (NPD).
“The technology is impressive as it can operate as a standalone
catheter or it can be easily integrated into existing ablation
catheters. It is unheard of to have such a clear and unaltered view
of the activity underneath the endocardium before, during and after
a cardiac ablation,” commented Terry Ransbury, NPD co-owner and
co-founder.
“We believe this technology can become integral to the detection
of gaps in lesions during an ablation procedure, which should
improve outcomes,” stated KC Armstrong, NPD co-owner and
co-founder. NPD is the development partner for LuxCath technology
and has been integral to developing and testing the LuxCath
systems.
More information about LuxCath can be found at www.luxcath.com.
The company is a subsidiary of Allied Minds. (LSE: ALM)
About LuxCath, LLCLuxCath is a leader in catheter-based,
real-time optical tissue-electrode contact assessment, lesion
progression monitoring, and lesion visualization for cardiac
ablation. LuxCath is focused on Atrial Fibrillation ablation as its
initial target market. The company’s patented technology involves
continuous optical tissue interrogation during ablation procedures.
It aims to improve clinical outcomes while reducing procedure
times, fluoroscopy exposure, costs, and clinical recurrences. More
information about LuxCath can be found on the web at
www.luxcath.com, or by calling 617.419.1800.
About Nocturnal Product Development (NPD)Nocturnal
Product Development is a multidisciplinary engineering group with
extensive experience in medical device development. Nocturnal
possesses not only the range and depth of engineering skills
necessary to bring medical devices to market, but also specific
clinical, pre-clinical, and market experience that sets it apart
from most design services companies. For more about Nocturnal
Product Development, visit www.nocturnalpd.com.
About Allied Minds, Inc.Allied Minds is an innovative
U.S. science and technology development and commercialization
company. Operating since 2006, Allied Minds forms, funds, manages
and builds products and businesses based on innovative technologies
developed at leading U.S. universities and federal research
institutions. Allied Minds serves as a diversified holding company
that supports its businesses and product development with capital,
central management and shared services. More information about the
Boston-based company can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company’s future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risk and uncertainties described in the risk factors
included in the company’s regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Prospectus Rules, the
Listing Rules and the Disclosure and Transparency Rules, neither
the company nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150728006893/en/
Media Contact:ArcPoint Strategic CommunicationsChristine
Dunn, 617-484-1660 x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024